Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Ariad Pharmaceuticals
So what: Shares bounced on positive results news about ridaforolimus, which treats advanced uterine cancer. The treatment was effective, but side effects were worse than some expected.
Now what: Overall this is positive news for Ariad and considering the pullback in shares later in the day might warrant a buying opportunity. Merck
Interested in more info on Ariad Pharmaceuticals? Add it to your watchlist here by clicking here.
Fool contributor Travis Hoium does not have a position in any company mentioned. You can follow Travis on Twitter at @FlushDrawFool, check out his personal stock holdings or follow his CAPS picks at TMFFlushDraw.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.